Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Nawal Ganai M Bahari

Biographic Data

ID8420494
NAMENawal Ganai M Bahari
GIVEN NAMESNawal Ganai M
FAMILY NAMEBahari
SIGNATUREBAHARI N G M
AFFILIATIONSNational Guard Health Affairs
VERIFIEDNo
TOTAL WORKS4
TOTAL CITATIONS0
WORKS AS AUTHOR4
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2019
LATEST PUBLICATION YEAR2023
H-INDEX0
  • Combination therapies

    Open Access•Nawal Hlal Almutairi, Nawal Ganai M Bahari et al.•ARTICLE•International Journal of Health…•2023

    Background: Tuberculosis (TB) is a significant global health issue requiring prolonged treatment regimens that often involve multiple medications. Mycobacterium tuberculosis, the causative agent, is capable of residing in various tissue compartments during infection, leading to variability in drug accessibility and susceptibility. The complexity of the infection necessitates the use of antibiotic combinations to ensure that all affected areas are…

  • Pharmaceutical supply chain management

    Open Access•Mariam Sabr Alshameri, Samar Saad Alotaibi et al.•ARTICLE•International Journal of Health…•2022

    Background: The globalization of pharmaceutical supply chains has exposed significant vulnerabilities, enabling counterfeit medications to infiltrate the market. These counterfeit drugs not only fail to aid in the recovery of patients but also pose serious health risks due to their inferior quality. The World Health Organization (WHO) reports that in developing nations, approximately 10% of medications consumed by patients are counterfeit. This a…

  • Rise of Biosimilars

    Open Access•Samar Saad Alotaibi, Nawal Hlal Almutairi et al.•ARTICLE•International Journal of Health…•2021

    Background: Biologics have transformed the management of immune-mediated inflammatory conditions, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The introduction of biosimilars—biologic medications that are highly similar and interchangeable with approved originators—has the potential to enhance market competition and improve patient access to necessary therapies. Aim of Work: This review aims to highlight the importance …

  • The impact of biotechnology on pharmaceutical manufacturing

    Open Access•Nawal Hlal Almutairi, Nawal Ganai M Bahari et al.•ARTICLE•International Journal of Health…•2019

    Background _ Bioengineering tools have revolutionized the production of pharmaceutical bioproducts by streamlining processes and reducing the time required for development. These tools are applicable across various biological platforms, including plants, animals, and microorganisms, offering substantial advantages in the pharmaceutical industry. Aim of Work – This review aims to highlight the benefits and advancements in bioengineering tools for …

No prominent works on this page.

  • The impact of biotechnology on pharmaceutical manufacturing

    Open Access•Nawal Hlal Almutairi, Nawal Ganai M Bahari et al.•ARTICLE•International Journal of Health…•2019

    Background _ Bioengineering tools have revolutionized the production of pharmaceutical bioproducts by streamlining processes and reducing the time required for development. These tools are applicable across various biological platforms, including plants, animals, and microorganisms, offering substantial advantages in the pharmaceutical industry. Aim of Work – This review aims to highlight the benefits and advancements in bioengineering tools for …

  • Rise of Biosimilars

    Open Access•Samar Saad Alotaibi, Nawal Hlal Almutairi et al.•ARTICLE•International Journal of Health…•2021

    Background: Biologics have transformed the management of immune-mediated inflammatory conditions, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The introduction of biosimilars—biologic medications that are highly similar and interchangeable with approved originators—has the potential to enhance market competition and improve patient access to necessary therapies. Aim of Work: This review aims to highlight the importance …

  • Pharmaceutical supply chain management

    Open Access•Mariam Sabr Alshameri, Samar Saad Alotaibi et al.•ARTICLE•International Journal of Health…•2022

    Background: The globalization of pharmaceutical supply chains has exposed significant vulnerabilities, enabling counterfeit medications to infiltrate the market. These counterfeit drugs not only fail to aid in the recovery of patients but also pose serious health risks due to their inferior quality. The World Health Organization (WHO) reports that in developing nations, approximately 10% of medications consumed by patients are counterfeit. This a…

  • Combination therapies

    Open Access•Nawal Hlal Almutairi, Nawal Ganai M Bahari et al.•ARTICLE•International Journal of Health…•2023

    Background: Tuberculosis (TB) is a significant global health issue requiring prolonged treatment regimens that often involve multiple medications. Mycobacterium tuberculosis, the causative agent, is capable of residing in various tissue compartments during infection, leading to variability in drug accessibility and susceptibility. The complexity of the infection necessitates the use of antibiotic combinations to ensure that all affected areas are…

Biotechnology and Related Fields (3 works) · Business (3 works) · Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Risk analysis (engineering (2 works) · Advanced Breast Cancer Therapies (1 work) · Biology (1 work) · Biosimilar (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Biotechnology (1 work)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae